For men suffering from enlarged prostate, Butterfly Medical is pushing a new standard of care. The medical device company, which offers a minimally invasive treatment for benign prostatic hyperplasia (BPH), has now closed a $21.0M Series C funding round.
The capital infusion, backed by investors including European Innovation Council, Junson Capital, MedVenture, and New Rhein Healthcare Investors, will support Butterfly Medical's patented technology. Its device provides an office-based alternative to traditional BPH surgery and long-term medication, designed for simple implantation under local anesthesia without incision or tissue removal.
